Rhythm Pharmaceuticals, Inc. (FRA:1RV)

Germany flag Germany · Delayed Price · Currency is EUR
87.00
+2.50 (2.96%)
At close: Dec 5, 2025
53.98%
Market Cap 6.00B
Revenue (ttm) 148.58M
Net Income (ttm) -168.51M
Shares Out n/a
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 4
Open 89.50
Previous Close 84.50
Day's Range 87.00 - 89.50
52-Week Range 41.00 - 98.50
Beta n/a
RSI 50.13
Earnings Date Feb 24, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 283
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1RV
Full Company Profile

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.